Thursday, November 19, 2026 Latest CDC: Flu Activity Rises Across US as 7 States Reach High Levels Our standards
Health

Galinpepimut-S Cuts Death Risk 41% in AML Trial

Galinpepimut-S cut the risk of death by 41 percent in a pivotal Phase 3 trial for acute myeloid leukemia, sending shares of its developer surging.

Sellas Life Sciences Shares Slide 10% After 0 Million Stock Sale Announced Following Trial-Driven Rally
Sellas Life Sciences Shares Slide 10% After $150 Million Stock Sale Announced Following Trial-Driven Rally

Galinpepimut-S cut the risk of death by 41 percent in a pivotal Phase 3 trial for acute myeloid leukemia, sending shares of its developer surging.

Participants could not undergo allogeneic stem cell transplantation, leaving them with limited options once the blood and bone marrow cancer returned.

“Those patients don't have any good therapy options, and that's where the current vaccine trial is placed to provide a benefit,” Dr. Ravi Majeti, a Stanford professor of medicine who was independent of the trial, told The Washington Post.

Investigators randomly assigned patients to receive either the vaccine or the best available treatment chosen by their doctors, which included observation, hypomethylating agents, venetoclax, and low-dose cytarabine.

Trial Shows Nine-Month Survival Gain

Median overall survival reached 24.0 months for patients receiving the vaccine compared with 14.7 months for the control arm, a nine-month difference, Tech Times reported. The analysis followed a pre-specified statistical plan triggered after 80 deaths occurred among the trial population.

The study recorded a hazard ratio of 0.59 and a two-sided p-value of 0.035. The treatment was generally well tolerated, with mild-to-moderate injection-site reactions reported as the most common adverse events.

“Patients go back to their lives, to their work, to their families,” Sellas CEO Angelos Stergiou told Fox & Friends.

Galinpepimut-S Cuts Death Risk 41% in AML Trial
Photo: Washington Post

The REGAL trial, identified as NCT04229979, was a global, randomized, open-label, registrational Phase 3 study that randomized 126 patients in a 1:1 ratio. The investigational arm received GPS maintenance therapy, while the control arm received investigator-selected best available treatment, which encompassed observation, azacitidine, decitabine, venetoclax, or low-dose cytarabine, alone or in permitted combinations, representing a choice of care rather than a single drug regimen.

The trial enrolled patients in second or later complete remission (CR2+) or CRp2+ after second- or later-line salvage therapy who were ineligible for or unable to undergo allogeneic stem cell transplant.

As of December 2025, SELLAS had reported 72 deaths in the trial and had expected the 80th event to be reached before the end of 2025; that threshold was ultimately reached only a few weeks before the November 17, 2026 announcement, triggering database lock, unblinding, and statistical analysis. The trial registry lists actual enrollment of 127 patients.

The vaccine targets WT1, a protein overexpressed across a broad range of blood cancers and solid tumors, including AML, and found in the cancer cells of more than 95% of people with AML.

Galinpepimut-S Cuts Death Risk 41% in AML Trial
Photo: Yahoo Finance

The vaccine was invented by David A. Scheinberg, MD, PhD, a leader in immunotherapy drug development at Memorial Sloan Kettering Cancer Center (MSK), who holds the Vincent Astor Chair. Scheinberg and his colleagues at MSK have been developing this peptide vaccine for more than two decades. Memorial Sloan Kettering and Dr. Scheinberg have financial interests related to SELLAS Life Sciences.

A Phase 2 study of the multivalent WT1 peptide vaccine (galinpepimut-S) in adults with AML in first complete remission (CR1) was conducted by researchers at Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, and the Sloan Kettering Institute. Published in Blood Advances on February 1, 2018, the study (authors: Maslak PG, Dao T, Bernal Y et al., 17 authors total) treated 22 patients (7 males; median age, 64 years).

Patients received 6 vaccinations over 10 weeks with the potential for 6 additional monthly doses if they remained in CR1. Fourteen patients (64%) completed at least 6 vaccinations, and 9 (41%) received all 12 doses. Fifteen patients (68%) relapsed, and 10 (46%) died.

Median disease-free survival from CR1 was 16.9 months, whereas overall survival from diagnosis had not yet been reached but was estimated to be at least 67.6 months. Nine of 14 tested patients (64%) had an immune response in at least one assay (CD4 or CD8).

The magnitude of the survival benefit observed with our investigational GPS cancer vaccine immunotherapy represents a defining milestone for Sellas and provides phase 3 validation of our WT1-targeted immunotherapeutic technology.

Angelos Stergiou, CEO of Sellas Life Sciences

Developed from four peptides, the vaccine trains the immune system to target the Wilms tumor 1 protein, which leukemia cells produce in excess. Researchers at Memorial Sloan Kettering Cancer Center spent more than two decades developing the immunotherapy, aiming to prevent relapse after primary treatment.

Galinpepimut-S Cuts Death Risk 41% in AML Trial
Photo: kalkine.ca

Stock Surges 156 Percent After Data Release

Following the trial announcement, Sellas Life Sciences stock surged 156 percent to close at $19.15 on Tuesday. The single-day rally added more than $2 billion in market value and lifted the company’s year-to-date gain to 408 percent.

“We made it to this point and continue to thrive because of our incredibly loyal shareholders who never lost faith, and an extraordinary team of just 14 people,” Sellas CEO Angelos Stergiou said.

The stock closed Monday near $7.50 and traded near $20 at the time of reporting, up about 150%, after touching highs around $25. Among biotech stocks worth at least $500 million, only Moderna and Adlai Nortye ranked ahead of Sellas. STAT columnist Adam Feuerstein acknowledged he had been wrong about GPS.

Hours after the data release, the company proposed a $150 million underwritten public offering of common stock to help fund development and a potential commercial launch. J.P. Morgan and TD Cowen are serving as joint book-running managers for the offering, which includes a 30-day option for underwriters to purchase up to an additional $22.5 million in shares.

The stock retreated about 10 percent in after-hours trading as investors weighed potential dilution from the new share sale. Sellas entered the offering with $134.7 million in cash and cash equivalents as of September 30. Shkreli has been consistently skeptical of SELLAS; earlier in 2026, he stated he was “very bearish“and that the trial”will fail,” questioning the peptide vaccine’s mechanism and the practical challenges of demonstrating a survival benefit in relapsed AML.

Sellas Plans FDA Meeting for Accelerated Filing

Sellas plans to meet with the Food and Drug Administration to discuss an accelerated filing strategy. The company is preparing a Biologics License Application targeting submission in the first half of 2027.

Detailed analyses of secondary endpoints, including leukemia-free survival and relapse-free survival, remain under way. The company plans to present those findings at an upcoming medical conference and submit them for peer-reviewed publication. SELLAS said evaluation of secondary endpoints and other prespecified analyses remained underway on Nov. 17.

The FDA has yet to set a decision date. The proposed submission would seek approval for maintenance treatment in the population studied in REGAL. In the fourth quarter of 2026 a second candidate is due to name its first target indication.

Acute myeloid leukemia accounts for about one in three leukemias in adults. Readers should consult qualified healthcare professionals for medical advice regarding treatment options.

Earlier coverage: GPS Vaccine Cuts AML Death Risk 41%, Study Finds

Accuracy matters. See something that needs attention? Read our corrections policy or contact the newsroom.

Health Editor

Nora Chen

Nora Chen leads TellingPointy's Health desk, covering medicine, public health, biotechnology, wellbeing, and health policy. Her desk distinguishes association from causation and early research findings from established clinical guidance.